Introduction Hypercortisolism leads to severe clinical consequences persisting after the onset of remission. These physical sequelae of cortisol exposure are known to profoundly impact the patient's quality of life. As psychological factors may be correlated with this quality of life, our objective was to determine the specific weight of psychological determinants of quality of life in patients in remission from hypercortisolism. Patients and methods In an observational study, 63 patients with hypercortisolism in remission were asked to complete exhaustive self-administered questionnaires including quality of life (WHOQoL-BREF and Cushing QoL), depression, anxiety, self-esteem, body image, and coping scales. Multivariate analyses were performed. Psychological variables relevant to the model were: anxiety, depression, self-esteem, body image, and positive thinking dimension of the Brief-COPE. Cortisol deficiency was defined as a potential confounder. Results The median time since remission was 3 years. Patients had significantly lower quality of life and body satisfaction score than the French population and patients with chronic diseases. Depression significantly impaired all WHOQoL and Cushing QoL domains. A low body satisfaction score significantly impaired social relationships quality of life score. In total, 42.9% of patients still needed working arrangements, 19% had disability or cessation of work. Conclusion Patients in biological remission of hypercortisolism can rarely be considered as functionally cured: this is evidenced by altered quality of life, working arrangements, and chronic depression. A multidisciplinary management of these patients is thus mandatory on a long-term basis.
Introduction
Hypercortisolism leads to severe clinical and biochemical consequences including increased cardiovascular risk (diabetes, obesity, hypertension, metabolic syndrome), hypercoagulability, osteoporosis, as well as psychiatric and cognitive disorders [1] [2] [3] such as depression or psychotic and manic symptoms [4] . Once remission is obtained, longterm physical sequelae of cortisol exposure are now well recognized and include a higher morbidity and mortality than in the general population [5] . This was shown, for instance, by Terzolo et al. [6] , who reported the persistence of obesity and hypertriglyceridemia 4 years after remission, whereas two other studies showed the persistence of an increased cardiovascular risk up to 5 years after remission [7, 8] .
The same holds true for neurocognitive impairment related to hypercortisolism. Even if psychiatric symptoms improve 1 year after the onset of eucortisolism, mental health does not always return to baseline. Anxio-depressive symptoms and suicidal thoughts can thus still be observed even several years after remission [9] . Several authors have evaluated patients' self-perceived health and their quality of life.
Quality of life was defined by WHO in 1993 as a broad ranging concept that is affected in a complex way by a person's physical health, but also their psychological state, personal beliefs, social relationships, and their environment. In a disease such as hypercortisolism, that is known to profoundly impact the social life of patients, precise characterization of quality of life is crucial. Quality of life impairment after eucortisolism has been clearly shown using several validated instruments regardless of etiology and treatment [10] . Tiemensma et al. [11] showed that patients' perceptions regarding their illness modified their quality of life even up to 15 years after remission.
As psychological and social factors may be correlated with the patient's quality of life, the main objective of this study was to determine the specific weight of psychological (anxiety and mood, coping, self-esteem) determinants of quality of life in patients in remission from hypercortisolism. The secondary objective was to describe the professional and social outcomes in these patients.
Patients and methods
A prospective monocentric, observational study was conducted in the Tertiary Center of La Conception Hospital, Assistance Publique Hôpitaux de Marseille, France.
Patients
All patients aged 18-80 who were in remission for 1-15 years from an endogenous hypercortisolism (ACTH dependent or ACTH independent) and regularly followed in our Center between January 2011 and December 2015 were included in the study. Patients were also identified via the database of "Association surrenales". Remission was defined as follows: eucortisolism (two normal measures of 24 h-urinary free cortisol, circadian cycle for cortisol defined by 08:00 cortisol over 350 nmol/L and 00:00 cortisol under 100 nmol/L) obtained by surgery, radiotherapy, or medical treatment, or hypocortisolism (08:00 cortisol under 138 nmol/L) with hydrocortisone replacement therapy. Of note, patients with genetic syndromes (Multiple Endocrine Neoplasia), plurihormonal pituitary adenoma, or pituitary carcinoma were not included in this study.
Data collection and conduct of the study
Informed written consent was obtained from all patients in the study, which was approved by a national ethics committee (Comite de protection des personnes Nord-Ouest III, identification 2017-A01949-44). The following data were collected for each patient: socio-demographic data (including age, gender, education level, lifestyle, profession, adaptation of workstation), medical data (treatment, medical history), hypercortisolism data (etiology of Cushing's syndrome, therapeutic course, actual treatment, delay in diagnosis, impairments, recurrence, duration of hypercortisolism).
Patients were also asked to complete the following selfadministered questionnaires:
Quality of life
• Quality of life was evaluated using a short generic, and a specific quality of life scale: the WHOQoL-BREF scale was developed by the WHOQoL Group in 1998 [12] , with a French version created in 2010 by Baumann et al. [13] . The only validated specific quality of life scale "the Cushing QoL" was also used [14] .
Psychosocial variables
• Anxiety and depression were evaluated using the HAD (Hospital Anxiety and Depression) scale. This scale, established by Zigmond in 1983 [15] and validated in French by Lepine [16] in 1985 helps to study both anxious and depressive components. Seven items are related to anxiety and seven related to depression giving two scores.
• Self-esteem was evaluated by the patients' own perceptions and Rosenberg's questionnaire developed in 1965 and translated in 1990 [17, 18] .
• Body image was evaluated by the IBQ (Image Body Questionnaire), a French questionnaire established by Bruchon-Schweitzer in 1990. A body satisfaction score was obtained with the IBQ [19] . Stunkard figurines were also used to explore body image. (Patients were asked to choose the shape that they believed was most representative of themselves).
• Coping strategies were also explored. Coping is defined as all the cognitive and behavioral adjustments that a person uses to deal with stressful situations about health and daily living [20] . The Brief-COPE explored 14 coping strategies (self-distraction, active coping, substance use, use of emotional support, use of instrumental support, humor, denial, behavioral disengagement, venting, positive reframing, planning, acceptance, religion, self-blame) [21] . A French-language four item questionnaire was used [22] to explore four coping strategies (avoidance including behavioral disengagement, self-distraction, substance use, denial and selfblame, problem solving including active coping and planning, seeking social support including emotional support, instrumental support, venting and religion, positive thinking including humor, positive reframing and acceptance). A situational scale (i.e., used for the assessment of situational coping responses to specific stressors) was also used [21, 22] .
Statistical analysis
We first performed a descriptive analysis of the population. Quantitative variables were expressed as median with interquartile ranges or means with standard deviation and qualitative variables were expressed as proportions and percentages. Quality of life scores (physical, psychological, and social relationship scores) of the generic scale were compared with age-and sex-matched French population norms [13] . Quality of life scores of the generic scale were correlated with quality of life scores of the specific scale (Cushing QoL).
Each Qol score was considered as a variable of interest: the four Qol scores of the WHOQoL-BREF (physical, psychological, social, and environmental scores) and the total score of the Cushing QoL. Univariate analyses were then carried out on all variables of interest using the following tests: non parametric test (Mann-Whitney), Spearman's Rho test and Kruskal-Wallis test (used for multimodal variables). Multivariate analyses using a multiple regression model (simultaneous model) were then performed. The variables relevant to the model (deficiencies, anxiety, depression, self-esteem, body image, and positive thinking dimension of the Brief-COPE) were selected from the univariate analysis, based on a threshold p value < 0.1 with cortisol deficiency, a priori, defined as a potential confounder. The final models incorporated the standardized β coefficients, which represent a change in the standard deviation of the quality of life domain resulting from a one standard deviation change in the various independent variables. (Higher standardized β coefficients have a greater relative effect on quality of life).
Data analyses were performed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL, USA). p values < 0.05 were considered significant and all statistical tests were two-tailed.
Results
Seventy-one patients were contacted and 63 patients (8 men and 55 women) were enrolled in this study, including 46 (73%) with ACTH-dependent Cushing's syndrome. As a first-line treatment, the majority of them underwent surgery after a median diagnostic delay of 2.5 years (1-5): 42 patients were treated by transsphenoidal surgery, 6 by bilateral adrenalectomy (negative pituitary MRI or contraindication for pituitary surgery, n = 3; ectopic ACTH secretion without visualized tumor, n = 1; bilateral adrenal hyperplasia, n = 2), and 13 by unilateral adrenalectomy. At inclusion, 79% (n = 50) of the patients presented with adrenal insufficiency treated by 20-30 mg/day hydrocortisone, and the median time since remission was 3 years (2-6). Of note, 30% of the patients had another pituitary deficiency. For 27% (n = 17) of the patients, inclusion was at the time of recurrence: 76% (n = 13) of the patients were treated by bilateral adrenalectomy (53% as a first-line treatment, 23% after medical treatment). The precise characteristics of the cohort are given in Annex. 1. Finally, most patients were educated to a high level, professionally active and had familial support. Socio-demographic characteristics are reported in Table 1 .
Quality of life
The quality of life scores of the WhoQoL-BREF that showed the greatest impairment were physical, then psychological, social relationships and last environment scores: (medians were 44 (31-56), 56 (44-69), 56 (50-75), and 69 (56-75), respectively). Patients had significantly lower quality of life scores than the overall French population matched for age and gender. (Fig. 1 ) All values are presented in numbers (n) and percentages % or median and interquartile range (IQR)
The median score for the Cushing QoL was 33 (27.5-39) . Specific and generic scales were well-correlated (with Spearman's Rho of physical, psychological, social, environment domains: 0.791, p < 0.001; 0.575, p < 0.001; 0.354, p < 0.01; 0.575, p < 0.001, respectively).
Psycho social data
• Self-esteem (Table 2) 39 patients (61.9 %) had a low or very low self-esteem, whereas 16 (25.4 %) had a high or very high self-esteem.
•
Body image
The body satisfaction score (IBQ) was significantly and inversely correlated with Stunkard body perception. Patients overall had a low body satisfaction score (Median (IQR): 56.5 (50.2-62)). The mean scores were 57.2 ± 7.1, and 54.3 ± 7.5 in females and males respectively: these scores were lower than in the French general population (mean of 72.9 ± 9 and 73.9 ± 10.5 in females and males, respectively, p < 0.001 for both).
• Anxiety and depression 36 patients (57.1%) had a HAD anxiety score above 8 (likely anxious), whereas 19 (30.2%) had a score above 11 (certain anxiety) ( Table 3) .
According to the HAD depression scale: 28 patients (44.4 %) had a depression score above 8 (likely depressive), and 10 (15.9 %) a score above 11 (certain depressive).
Of note, the length of remission did not significantly improve the anxiety and depression scores (Annex. 2). Seventeen patients (27%) received psychiatric treatment (mainly antidepressants and anxiolytics) at inclusion. Treated-group depression scores were significantly higher in the treated vs the untreated group. (mean ± SD, respectively, 9 ± 3.4 vs 5.5 ± 3.5, p < 0.001)
•

Coping strategies
The adaptation strategy preferentially adopted by patients was to seek social support then to avoid it.
• Professional impact Fig. 1 WHOQoL-BREF quality of life scores (Transformed scores from 0 to 100, higher scores corresponding to higher QoL). *** p < 0.001 In total, 42.9 % of the patients required adaptation of their workstation at the time of this study. Only 25.4 % of the patients occupied the same position as before the management of hypercortisolism, without requiring any adaptation. Details of the professional impacts are reported in Table 3 .
Quality of life determinants
Variables of interest tested in the univariate analysis are reported in Annex. 3 (clinical and socio-demographic data) and 4 (psychological data).
Using univariate analysis, no association was found between quality of life and age, associated pituitary deficiencies, lifestyle, and duration of exposure to hypercortisolism (before diagnosis).
In multivariate analysis, depression was the only marker impairing all WHOQoL and Cushing QoL domains. Cortisol deficiency significantly impaired both physical quality of life score and the measured Cushing QoL score. A low body satisfaction score significantly impaired social relationships quality of life score. There was a strong trend for a correlation between positive thinking and the environment domain of quality of life (p < 0.054). (Table 4 ). The links between quality of life domains (specific and generic scale) and the variables of interest, which were not relevant to the model and with a p value < 0.1 in univariate analysis are reported in Annex. 3 and 4.
Discussion
To our knowledge, our study is the first that allows an exhaustive analysis of the psychosocial characteristics, leading to long-term quality of life impairments in patients in remission of Cushing's syndrome. We showed that functional remission did not occur for most of the patients considered to be in biochemical and clinical remission. Functional remission is a psychiatric concept defined by the association of clinical remission and a recovery of social, professional, and personal levels of functioning. In our patients, who were in biochemical remission, the quality of life remained impaired in all domains as has been reported in previous studies [23] . Furthermore, our patients presented a quality of life index that was lower than in patients suffering from chronic diseases [13] . In psychiatry, it is well known that the time needed to obtain functional remission in depressed patients can be up to three times longer than the time needed to obtain clinical remission [24] . This time course is very similar to what is observed in patients after remission of hypercortisolism: it suggests that this concept should be applied to hypercortisolism (especially as patients with Cushing's syndrome suffer frequently from anxiety and depression) to better explain the mid-term outcome of these patients [10] . Depression and anxiety occurred in nearly half of the patients. Cushing's patients were more depressed than the general French population (INPES, 2010). However, in our patients, this issue was likely under-diagnosed and undertreated: indeed, only 27% of our patients received psychiatric care (drug treatment or psychotherapy). Consistent with previous studies, depression significantly impaired all WHOQoL domains and Cushing QoL [25, 26] . In such patients, the first-line therapy in major depressive episodes should be Selective Serotonin Reuptake Inhibitors (SSRI) as suggested by Santos et al. [25] in line with recommendations for the general population. Fluoxetin could be of particular interest, as it is known to improve dysmorphophobia [27] and quality of life after stroke in patients with high cardiovascular risk [28] , two characteristics that have also been reported in patients exposed to hypercortisolism. Moreover, although hippocampal atrophy improves after cure of hypercortisolism, recovery from functional and neuronal injuries is inconsistent [29, 30] . The fact that fluoxetin improves neurogenesis is an additional argument in favor of this drug being used as first-line treatment [31] . In view of the major impairment of our patients' quality of life owing to depressive symptomatology, we thus recommend early diagnosis and treatment with SSRI, especially fluoxetin.
After remission, patients exposed to hypercortisolism still suffer from dysmorphophobia, a characteristic that is correlated with the impaired social relationships quality of life domain but not with physical domain. In our patients, negative self-perception had a negative impact on social life. Tiemensma et al. [32] showed that body perception was still impaired after a prolonged follow-up of hypercortisolic patients who had been cured. In the same study, in their drawing test (showing their cured state), patients represented themselves with a thinner abdomen width and a thinner head than in drawings showing active disease state. This meant that their perceived body did not completely return to the original shape. However, surprisingly, and in contrast to our study, the authors did not report a correlation between impaired body perception and impaired quality of life. In our patients, who represent a population investigated after a shorter period of remission, cured body mass index (BMI) was correlated with physical domain of quality of life. Two previous studies on the same topic showed contradictory results for the correlations between BMI and quality of life [26, 33] . These discrepancies could be explained by different lengths of follow-up after remission. Finally, we believe that therapy around patient body image should be proposed to all the patients after cure, as soon as the BMI has become stable. Indeed, Geer et al. [34] showed that patients did not report an improvement in feelings of fullness and post-prandial satisfaction up to 42 months after Cushing's remission. It should be mentioned that in addition to negative self-perception, patients with Cushing's syndrome even if cured, actually have persistence of visceral obesity and waist circumference larger than controls and it is quite unfrequent that their body returns to the original shape; the body mass index alone is not representative of cortisol dependent body changes. It is thus highly likely that quality of life would be improved through appropriate multidisciplinary care related to nutritional and physical rehabilitation.
Our study has several potential limitations owing to the rarity of the disease. The first may relate to the high proportion of patients with cortisol insufficiency, a disease that is considered to be a determinant of physical quality of life impairment per se. However, De Bucy et al. [35] showed that hypercortisolic patients have a significantly more impaired physical quality of life when they become deficient, in comparison with patients with Addison's disease, and a statistical trend of having an impaired social relationships quality of life domain. Moreover, patients suffering from primary adrenal insufficiency present with different neurocognitive impairments: they are indeed sensitive and hypervigilant, but not depressed or anxious compared with the general population. Both profiles thus seem very different, which suggests that exposure to hypercortisolism is a major determinant of quality of life per se [36, 37] . A second limitation of our study could be the high educational level of our patients, which may not be representative of the general population of patients with hypercortisolism. This high educational level may decrease the negative impact of hypercortisolism on cognitive functions due to a higher cognitive reserve. The cognitive reserve is defined as the level of injuries a brain can tolerate before reaching a critical threshold beyond which clinical deficiencies appear. Educational level, professional achievement, or leisure activities involving complex cognitive processes are indeed considered to be protective factors for neurocognitive impairment. Kesler et al. [38] reported that brain atrophy in highly educated patients was lower than that in less-educated patients of the same age. As brain exposure to hypercortisolism is considered to be a brain injury leading to adaptive mechanisms correlated to the cognitive reserve [39, 40] , cognitive results of lesseducated patients could thus have been worse than in our cohort. Finally, the majority of included patients were females, and it might be possible that different results would be observed with in male patients with Cushing's syndrome.
To conclude, in all chronic endocrine diseases, evaluation of self-perceived health has become a challenging task for endocrinologists. This is especially the case for patients with Cushing's syndrome. Indeed, despite clinical and biochemical remission, patients exposed to hypercortisolism do not show functional remission. As the predominant impairment concerns the physical domain, cautious patient care should be scaled up (with occupational and physical therapy) to improve physical consequences and body image. Of note, this impaired quality of life is strongly correlated to neurocognitive damage, and especially depression, a condition that is frequently confounded with the poor general condition owing to the decreased levels of cortisol. A psychiatric consultation should thus be systematically advised, and SSRI therapy should be discussed. Future prospective studies should be aimed at evaluating the quality of techniques aimed at helping the patients, their carers, and family.
